English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The non-Vitamin K oral anticoagulants (NOACs) help prevent stroke in patients of atrial fibrillation. However, management of patients on NOACs in emergency situations is a challenging prospect. Idarucizumab is approved globally as well as in India as the specific reversal agent for dabigatran. We report two cases with successful reversal using Idarucizumab in acute ischemic stroke and intracranial hemorrhage. © 2019 Published by Innovative Publication.

ip indian journal of neurosciences/ip indian journal of neurosciences

Reversal of the anticoagulant effect of direct thrombin inhibitor dabigatran etexilate in acute ischemic stroke and intracranial hemorrhage using idarucizumab – A case study